Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)

被引：0
|
作者：
E Schuler
A Giagounidis
D Haase
K Shirneshan
G Büsche
U Platzbecker
F Nolte
K Götze
R F Schlenk
A Ganser
A Letsch
F Braulke
M Lübbert
G Bug
P Schafhausen
U Bacher
N Gattermann
M Wulfert
R Haas
U Germing
机构：
[1] Oncology and Clinical Immunology,Department for Hematology
[2] University Hospital,Department of Hematology
[3] Heinrich-Heine-University,Department of Hematology
[4] Oncology and Palliative Care,Department of Hematology and Oncology
[5] Marien Hospital Duesseldorf,Department of Internal Medicine
[6] University Medicine Goettingen,Department of Internal Medicine
[7] Clinics of Hematology and Medical Oncology,Department of Hematology
[8] Hannover Medical School,Department of Hematology and Oncology
[9] Institute of Pathology,Department of Internal Medicine
[10] University Hospital Dresd,Department of Oncology
[11] en,undefined
[12] University Hospital Mannheim,undefined
[13] Technical University of Munich,undefined
[14] University Hospital Ulm,undefined
[15] Hemostasis,undefined
[16] Oncology,undefined
[17] and Stem Cell Transplantation,undefined
[18] Hannover Medical School,undefined
[19] Charité,undefined
[20] Benjamin Franklin University,undefined
[21] University Hospital Freiburg,undefined
[22] Internal Medicine,undefined
[23] University Hospital Frankfurt,undefined
[24] Hematology,undefined
[25] BMT with section Pneumology,undefined
[26] Hubertus Wald Cancer Center,undefined
[27] University Medical Center Hamburg-Eppendorf,undefined
来源：
Leukemia | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1580 / 1582
页数：2
相关论文
共 50 条
  • [1] Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
    Schuler, E.
    Giagounidis, A.
    Haase, D.
    Shirneshan, K.
    Buesche, G.
    Platzbecker, U.
    Nolte, F.
    Goetze, K.
    Schlenk, R. F.
    Ganser, A.
    Letsch, A.
    Braulke, F.
    Luebbert, M.
    Bug, G.
    Schafhausen, P.
    Bacher, U.
    Gattermann, N.
    Wulfert, M.
    Haas, R.
    Germing, U.
    LEUKEMIA, 2016, 30 (07) : 1580 - 1582
  • [2] RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
    Schuler, E.
    Schemenau, J.
    Giagounidis, A.
    Haase, D.
    Bueshce, G.
    Platzbecker, U.
    Nolte, F.
    Goetze, K.
    Schlenk, R. F.
    Ganser, A.
    Letsch, A.
    Luebbert, M.
    Schafhausen, P.
    Bug, G.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S62 - S62
  • [3] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [4] Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
    Talati, Chetasi
    Sallman, David
    List, Alan
    SEMINARS IN HEMATOLOGY, 2017, 54 (03) : 159 - 166
  • [5] Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial
    Almeida, Antonio
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Goldberg, Stuart L.
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Castaneda, Carmen
    Zhong, Jianhua
    Beach, C. L.
    Santini, Valeria
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2135 - 2143
  • [6] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
    Heise, Carla
    Carter, Troy
    Schafer, Peter
    Chopra, Rajesh
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
  • [7] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [8] MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES
    Martinez-Hoyer, Sergio
    Deng, Yu
    Parker, Jeremy
    Jiang, Jihong
    Docking, Roderick
    Mo, Angela
    Gharaee, Nadia
    Jadersten, Martin
    Kulasekararaj, Austin
    Malcovati, Luca
    List, Alan
    Hellstrom-Lindberg, Eva
    Platzbecker, Uwe
    Karsan, Aly
    EXPERIMENTAL HEMATOLOGY, 2020, 88 : S72 - S72
  • [9] TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q) treated with lenalidomide: Results from the German Le-Mon-5 trial
    Mossner, M.
    Platzbecker, U.
    Giagounidis, A.
    Goetze, K.
    Letsch, A.
    Haase, D.
    Schlenk, R.
    Bug, G.
    Luebbert, M.
    Ganser, A.
    Jann, J. C.
    Oblaender, J.
    Fey, S.
    Hofmann, W. K.
    Germing, U.
    Nolte, F.
    LEUKEMIA RESEARCH, 2013, 37 : S165 - S165
  • [10] Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
    Mallo, Mar
    del Rey, Monica
    Ibanez, Mariam
    Jose Calasanz, Ma
    Arenillas, Leonor
    Jose Larrayoz, Ma
    Pedro, Carmen
    Jerez, Andres
    Maciejewski, Jaroslaw
    Costa, Dolors
    Nomdedeu, Meritxell
    Diez-Campelo, Maria
    Lumbreras, Eva
    Gonzalez-Martinez, Teresa
    Marugan, Isabel
    Such, Esperanza
    Cervera, Jose
    Cigudosa, Juan C.
    Alvarez, Sara
    Florensa, Lourdes
    Hernandez, Jesus Ma
    Sole, Francesc
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 74 - 86
12345